Seminars in Oncology
Volume 34, Issue 6 , Pages 452-459 , December 2007

Genetics: What Advice for Patients Who Present With a Family History of Melanoma?

  • Julia A. Newton Bishop

      Affiliations

    • Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, St James’s Hospital, Leeds, United Kingdom.
    • Corresponding Author InformationAddress correspondence to Julie A. Newton Bishop, MD, FRCP, Section of Epidemiology and Biostatistics, Leeds Institute of Molecular Medicine, St James’s Hospital, Leeds, UK LS9 7TF.
    • ,
  • Nelleke A. Gruis

      Affiliations

    • Skin Research Laboratory, Leiden University Medical Center, Leiden, The Netherlands.

References 

  1. de Vries E, Bray FI, Coebergh JW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997: Rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer. 2003;107:119–126
  2. La Vecchia C, Lucchini F, Negri E, et al. Recent declines in worldwide mortality from cutaneous melanoma in youth and middle age. Int J Cancer. 1999;81:62–66
  3. Aitken JF, Duffy DL, Green A, et al. Heterogeneity of melanoma risk in families of melanoma patients. Am J Epidemiol. 1994;140:961–973
  4. Begg CB, Hummer A, Mujumdar U, et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control. 2004;15:957–965
  5. Kerber RA, O’Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer. 2005;103:1906–1915
  6. Kaye FJ, Harbour JW. For whom the bell tolls: Susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst. 2004;96:342–343
  7. Liede A, Karlan BT, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J Clin Oncol. 2004;22:735–742
  8. Tonin PN. Genes implicated in hereditary breast cancer syndromes. Semin Surg Oncol. 2000;18:281–286
  9. Potzsch C, Voigtlander T, Lubbert M. p53 Germline mutation in a patient with Li-Fraumeni syndrome and three metachronous malignancies. J Cancer Res Clin Oncol. 2002;128:456–460
  10. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Human Mol Genet. 1996;5:1663–1666
  11. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358–5362
  12. Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44:99–106
  13. Kamb A, Gruis N, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436–440
  14. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet. 1994;8:22–26
  15. Cannon-Albright LA, Goldgar DE, Neuhausen S, et al. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics. 1994;23:265–268
  16. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellular senescence in naevi and immortalisation in melanoma: A role for p16?. Br J Cancer. 2006;95:496–505
  17. Chin L, Pomerantz J, DePinho RA. The INK4a/ARF tumor suppressor: One gene—two products—two pathways. Trends Biochem Sci. 1998;23:291–296
  18. Rizos H, Woodruff S, Kefford RF. p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partners. Cell Cycle. 2005;4:597–603
  19. Gallagher SJ, Kefford RF, Rizos H. The ARF tumour suppressor. Int J Biochem Cell Biol. 2006;38:1637–1641
  20. Randerson-Moor JA, Harland M, Williams S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet. 2001;10:55–62
  21. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene. 2001;20:5543–5547
  22. Hewitt C, Lee Wu C, Evans G, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11:1273–1279
  23. Harland M, Taylor CF, Chambers PA, et al. A mutation hotspot at the p14ARF splice site. Oncogene. 2005;24:4604–4608
  24. Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res. 2002;12:51–55
  25. Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France (The French Familial Melanoma Study Group). Hum Mol Genet. 1998;7:209–216
  26. Molven A, Grimstvedt MB, Steine SJ, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer. 2005;44:10–18
  27. Mistry SH, Taylor C, Randerson-Moor JA, et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer. 2005;44:292–300
  28. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med. 1989;320:1367–1372
  29. Gillanders E, Hank Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet. 2003;73:301–313
  30. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818–9828
  31. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894–903
  32. Platz A, Hansson J, Mansson-Brahme E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst. 1997;89:697–702
  33. Gruis NA, Sandkuijl LA, van der Velden PA, et al. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res. 1995;5:169–177
  34. Ciotti P, Struewing JP, Mantelli M, et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet. 2000;67:311–319
  35. Bergman W, Watson P, de Jong J, et al. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990;61:932–936
  36. Lynch HT, Fusaro RM. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas. 1991;6:127–131
  37. Ghiorzo P, Ciotti P, Mantelli M, et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer. 1999;83:441–448
  38. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A. 2006;103:5947-5452
  39. Bahuau M, Vidaud D, Jenkins RB, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 1998;58:2298–2303
  40. Azizi E, Freidman J, Pavolotky F, et al. Familial cutaneous malignant melanoma and tumours of the nervous system. Cancer. 1995;76:1571–1578
  41. Clark WH, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions (’The B-K mole syndrome’). Arch Dermatol. 1978;114:732–738
  42. Lynch HT, Fusaro RM, Kimberling WJ, et al. Familial atypical multiple mole-melanoma (FAMMM) syndrome; segregation analysis. J Med Genet. 1983;20:342–344
  43. Clark WH. Human cutaneous malignant melanoma as a model for cancer. Cancer Metastas Rev. 1991;10:83–88
  44. Annessi G, Cattaruzza MS, Abeni D, et al. Correlation between clinical atypia and histologic dysplasia in acquired melanocytic nevi. J Am Acad Dermatol. 2001;45:77–85
  45. Bergman W, Palan A, Went LN. Clinical and genetic studies in six Dutch kindreds with the dysplastic naevus syndrome. Ann Hum Genet. 1986;50:249–258
  46. Bishop JA, Wachsmuth RC, Harland M, et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol. 2000;114:28–33
  47. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: I (Common and atypical naevi). Eur J Cancer. 2005;41:28–44
  48. Zhu G, Duffy DL, Eldridge A, et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet. 1999;65:483–492
  49. Bataille V, Sneider H, MacGregor A, et al. Genetics of risk factors for melanoma: an adult twin study of nevi and freckles. J Natl Cancer Inst. 2000;92:457–463
  50. Wachsmuth RC, Gaut RM, Barrett JH, et al. Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol. 2001;117:348–352
  51. Barrett JH, Gaut R, Wachsmuth R, et al. Linkage and association analysis of nevus density and the region containing the melanoma gene CDKN2A in UK twins. Br J Cancer. 2003;88:1920–1924
  52. Zhu G, Montgomery GW, James MR, et al. A genome-wide scan for naevus count: Linkage to CDKN2A and to other chromosome regions. Eur J Hum Genet. 2007;15:94–102
  53. Falchi M, Spector TD, Perks U, et al. Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort. Hum Mol Genet. 2006;15:2975–2979
  54. Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol. 2002;3:653–654
  55. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma?. Curr Opin Oncol. 2003;15:157–161
  56. Parkin D, Whelan S, Ferlay J, et al. Cancer Incidence in Five Continents (IARC Scientific Publications No. 143). Lyon, France: International Agency for Research on Cancer; 1997;
  57. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III (Family history, actinic damage and phenotypic factors). Eur J Cancer. 2005;41:2040–2059
  58. Orlow SJ, Brilliant MH. The pink-eyed dilution locus controls the biogenesis of melanosomes and levels of melanosomal proteins in the eye. Exp Eye Res. 1999;68:147–154
  59. Chen K, Manga P, Orlow SJ. Pink-eyed dilution protein controls the processing of tyrosinase. Mol Biol Cell. 2002;13:1953–1964
  60. Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995;11:328–330
  61. Bastiaens M, ter Huurne J, Gruis N, et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet. 2001;10:1701–1708
  62. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype?. Am J Hum Genet. 2000;66:176–186
  63. Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet. 2003;41:e13
  64. Gruis N, Van Der Velden P, Sandkuijl L, et al. Melanocortin 1 receptor (MC1R) variant Arg151Cys is generally associated with fair skin and modifies risk in Dutch familial atypical multiple mole melanoma (FAMMM) syndrome families. Am J Hum Genet. 1997;61:A200
  65. van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet. 2001;69:774–779
  66. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet. 2001;69:765–773
  67. Kanetsky PA, Swoyer J, Panossian S, et al. A polymorphism in the agouti signaling protein gene is associated with human pigmentation. Am J Hum Genet. 2002;70:770–775
  68. Landi MT, Kanetsky PA, Tsang S, et al. MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst. 2005;97:998–1007
  69. Meziani R, Descamps V, Gerard B, et al. Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. J Dermatol Sci. 2005;40:133–136
  70. Rebbeck TR, Kanetsky PA, Walker AH, et al. P gene as an inherited biomarker of human eye color. Cancer Epidemiol Biomarkers Prev. 2002;11:782–784
  71. Duffy DL, Box NF, Chen W, et al. Interactive effects of MC1R and OCA2 on melanoma risk phenotypes. Hum Mol Genet. 2004;13:447–461
  72. Jannot AS, Meziani R, Bertrand G, et al. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet. 2005;13:913–920
  73. Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: II (Sun exposure). Eur J Cancer. 2005;41:45–60
  74. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol. 1980;9:227–231
  75. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004;80(suppl 6):1678S–1688S
  76. Holick MF. Vitamin D: Its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006;2:49–59

 Supported by Cancer Research UK, the NIH (RO1-CA-083115-06), and Framework 6 (J.A.N.B.). Professor Newton Bishop and Dr Gruis are Coordinator and Vice Coordinator, respectively, of GenoMEL, the melanoma genetics consortium (www.genomel.org).

PII: S0093-7754(07)00182-0

doi: 10.1053/j.seminoncol.2007.09.006

Seminars in Oncology
Volume 34, Issue 6 , Pages 452-459 , December 2007

Article Tools

* Image Usage & Resolution